Cargando…
A novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway
BACKGROUND: Multiple myeloma (MM) is a highly aggressive and incurable clonal plasma cell disease with a high rate of recurrence. Thus, the development of new therapies is urgently needed. DCZ0805, a novel compound synthesized from osalmide and pterostilbene, has few observed side effects. In the cu...
Autores principales: | Gao, Xuejie, Li, Bo, Ye, Anqi, Wang, Houcai, Xie, Yongsheng, Yu, Dandan, Xu, Zhijian, Shi, Bingqing, Zhang, Hui, Feng, Qilin, Hu, Ke, Zhang, Yong, Huang, Cheng, Yang, Guang, Shi, Jumei, Zhu, Weiliang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165811/ https://www.ncbi.nlm.nih.gov/pubmed/34053438 http://dx.doi.org/10.1186/s12935-021-01973-1 |
Ejemplares similares
-
Glycolysis is suppressed by DCZ0801-induced inactivation of the Akt/mTOR pathway in Multiple Myeloma
por: Feng, Qilin, et al.
Publicado: (2020) -
A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe
por: Hu, Liangning, et al.
Publicado: (2020) -
The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13–MAPK–YWHAE signaling pathway
por: Wang, Yingcong, et al.
Publicado: (2023) -
Preclinical activity of DCZ3301, a novel aryl-guanidino compound in the therapy of multiple myeloma
por: Gao, Minjie, et al.
Publicado: (2017) -
DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway
por: Sun, Xi, et al.
Publicado: (2017)